Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma

The response to immunotherapy of melanoma patients is heterogeneous. Here, the authors demonstrate that a high expression of the two major components of the immunoproteasome, PSMB8 and PSMB9, modulates the production of HLA peptides and it is predictive of better survival and improved response to im...

Full description

Bibliographic Details
Main Authors:	Shelly Kalaora, Joo Sang Lee, Eilon Barnea, Ronen Levy, Polina Greenberg, Michal Alon, Gal Yagel, Gitit Bar Eli, Roni Oren, Aviyah Peri, Sushant Patkar, Lital Bitton, Steven A. Rosenberg, Michal Lotem, Yishai Levin, Arie Admon, Eytan Ruppin, Yardena Samuels
Format:	Article
Language:	English
Published:	Nature Publishing Group 2020-02-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-020-14639-9

id	doaj-c5c1da08d4014458bca5479e40d5cf1c
record_format	Article
spelling	doaj-c5c1da08d4014458bca5479e40d5cf1c2021-05-11T08:07:39ZengNature Publishing GroupNature Communications2041-17232020-02-0111111210.1038/s41467-020-14639-9Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanomaShelly Kalaora0Joo Sang Lee1Eilon Barnea2Ronen Levy3Polina Greenberg4Michal Alon5Gal Yagel6Gitit Bar Eli7Roni Oren8Aviyah Peri9Sushant Patkar10Lital Bitton11Steven A. Rosenberg12Michal Lotem13Yishai Levin14Arie Admon15Eytan Ruppin16Yardena Samuels17Department of Molecular Cell Biology, Weizmann Institute of ScienceCancer Data Science Lab, National Cancer InstituteDepartment of Biology, TechnionDepartment of Molecular Cell Biology, Weizmann Institute of ScienceDepartment of Molecular Cell Biology, Weizmann Institute of ScienceDepartment of Molecular Cell Biology, Weizmann Institute of ScienceDepartment of Molecular Cell Biology, Weizmann Institute of ScienceDepartment of Molecular Cell Biology, Weizmann Institute of ScienceDepartment of Veterinary Resources, Weizmann Institute of ScienceDepartment of Molecular Cell Biology, Weizmann Institute of ScienceCancer Data Science Lab, National Cancer InstituteDepartment of Molecular Cell Biology, Weizmann Institute of ScienceThe Surgery Branch, National Cancer InstituteSharett Institute of Oncology, Hadassah Medical SchoolNancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of ScienceDepartment of Biology, TechnionCancer Data Science Lab, National Cancer InstituteDepartment of Molecular Cell Biology, Weizmann Institute of ScienceThe response to immunotherapy of melanoma patients is heterogeneous. Here, the authors demonstrate that a high expression of the two major components of the immunoproteasome, PSMB8 and PSMB9, modulates the production of HLA peptides and it is predictive of better survival and improved response to immune-checkpoint inhibitors of melanoma patients.https://doi.org/10.1038/s41467-020-14639-9
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Shelly Kalaora Joo Sang Lee Eilon Barnea Ronen Levy Polina Greenberg Michal Alon Gal Yagel Gitit Bar Eli Roni Oren Aviyah Peri Sushant Patkar Lital Bitton Steven A. Rosenberg Michal Lotem Yishai Levin Arie Admon Eytan Ruppin Yardena Samuels
spellingShingle	Shelly Kalaora Joo Sang Lee Eilon Barnea Ronen Levy Polina Greenberg Michal Alon Gal Yagel Gitit Bar Eli Roni Oren Aviyah Peri Sushant Patkar Lital Bitton Steven A. Rosenberg Michal Lotem Yishai Levin Arie Admon Eytan Ruppin Yardena Samuels Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma Nature Communications
author_facet	Shelly Kalaora Joo Sang Lee Eilon Barnea Ronen Levy Polina Greenberg Michal Alon Gal Yagel Gitit Bar Eli Roni Oren Aviyah Peri Sushant Patkar Lital Bitton Steven A. Rosenberg Michal Lotem Yishai Levin Arie Admon Eytan Ruppin Yardena Samuels
author_sort	Shelly Kalaora
title	Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma
title_short	Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma
title_full	Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma
title_fullStr	Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma
title_full_unstemmed	Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma
title_sort	immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma
publisher	Nature Publishing Group
series	Nature Communications
issn	2041-1723
publishDate	2020-02-01
description	The response to immunotherapy of melanoma patients is heterogeneous. Here, the authors demonstrate that a high expression of the two major components of the immunoproteasome, PSMB8 and PSMB9, modulates the production of HLA peptides and it is predictive of better survival and improved response to immune-checkpoint inhibitors of melanoma patients.
url	https://doi.org/10.1038/s41467-020-14639-9
work_keys_str_mv	AT shellykalaora immunoproteasomeexpressionisassociatedwithbetterprognosisandresponsetocheckpointtherapiesinmelanoma AT joosanglee immunoproteasomeexpressionisassociatedwithbetterprognosisandresponsetocheckpointtherapiesinmelanoma AT eilonbarnea immunoproteasomeexpressionisassociatedwithbetterprognosisandresponsetocheckpointtherapiesinmelanoma AT ronenlevy immunoproteasomeexpressionisassociatedwithbetterprognosisandresponsetocheckpointtherapiesinmelanoma AT polinagreenberg immunoproteasomeexpressionisassociatedwithbetterprognosisandresponsetocheckpointtherapiesinmelanoma AT michalalon immunoproteasomeexpressionisassociatedwithbetterprognosisandresponsetocheckpointtherapiesinmelanoma AT galyagel immunoproteasomeexpressionisassociatedwithbetterprognosisandresponsetocheckpointtherapiesinmelanoma AT gititbareli immunoproteasomeexpressionisassociatedwithbetterprognosisandresponsetocheckpointtherapiesinmelanoma AT ronioren immunoproteasomeexpressionisassociatedwithbetterprognosisandresponsetocheckpointtherapiesinmelanoma AT aviyahperi immunoproteasomeexpressionisassociatedwithbetterprognosisandresponsetocheckpointtherapiesinmelanoma AT sushantpatkar immunoproteasomeexpressionisassociatedwithbetterprognosisandresponsetocheckpointtherapiesinmelanoma AT litalbitton immunoproteasomeexpressionisassociatedwithbetterprognosisandresponsetocheckpointtherapiesinmelanoma AT stevenarosenberg immunoproteasomeexpressionisassociatedwithbetterprognosisandresponsetocheckpointtherapiesinmelanoma AT michallotem immunoproteasomeexpressionisassociatedwithbetterprognosisandresponsetocheckpointtherapiesinmelanoma AT yishailevin immunoproteasomeexpressionisassociatedwithbetterprognosisandresponsetocheckpointtherapiesinmelanoma AT arieadmon immunoproteasomeexpressionisassociatedwithbetterprognosisandresponsetocheckpointtherapiesinmelanoma AT eytanruppin immunoproteasomeexpressionisassociatedwithbetterprognosisandresponsetocheckpointtherapiesinmelanoma AT yardenasamuels immunoproteasomeexpressionisassociatedwithbetterprognosisandresponsetocheckpointtherapiesinmelanoma
_version_	1721451203278143488

Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma

Similar Items